These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26979821)

  • 1. [Not Available].
    Kurth A
    Unfallchirurg; 2016 Mar; 119(3):174-5. PubMed ID: 26979821
    [No Abstract]   [Full Text] [Related]  

  • 2. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab is an option for treatment of osteoporosis.
    Simonelli C
    Am Fam Physician; 2012 Dec; 86(11):992; author reply 994. PubMed ID: 23198660
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous ibandronate (Boniva).
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):68-9. PubMed ID: 16977282
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An advantage for compliance: alendronate once weekly].
    MMW Fortschr Med; 2005 Dec; 147(49-50):75. PubMed ID: 16401017
    [No Abstract]   [Full Text] [Related]  

  • 7. [FACT study].
    Tanaka I; Oshima H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():280-5. PubMed ID: 18161120
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibandronic acid IV: new formulation. Unconvincing evidence.
    Prescrire Int; 2008 Feb; 17(93):10. PubMed ID: 18354845
    [No Abstract]   [Full Text] [Related]  

  • 9. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.
    Watts NB; Bilezikian JP; Camacho PM; Greenspan SL; Harris ST; Hodgson SF; Kleerekoper M; Luckey MM; McClung MR; Pollack RP; Petak SM;
    Endocr Pract; 2010; 16 Suppl 3(Suppl 3):1-37. PubMed ID: 21224201
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
    Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
    Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
    Thiebaud D
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
    [No Abstract]   [Full Text] [Related]  

  • 14. [Not Available].
    Chanson P
    Rev Prat; 2013 Sep; 63(7):924. PubMed ID: 24167890
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathologizing old age: the case of osteoporosis.
    Grob GN
    MD Advis; 2011; 4(2):20-2, 24-7. PubMed ID: 21637178
    [No Abstract]   [Full Text] [Related]  

  • 16. [Long term effects of raloxifen on the bones].
    Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):224-6. PubMed ID: 18282451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
    Felsenberg D; Bock O; Börst H; Armbrecht G; Beller G; Degner C; Stephan-Oelkers M; Schacht E; Mazor Z; Hashimoto J; Roth HJ; Martus P; Runge M
    J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
    Endo I; Matsumoto T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
    [No Abstract]   [Full Text] [Related]  

  • 20. [Men also need bone protection].
    MMW Fortschr Med; 2006 Nov; 148(46):48-9. PubMed ID: 17615790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.